EZH2 and cancer: The combination (F2C) alleviated the proliferative malignancy of the cancer cells by downregulating enhancer of zest homolog 2 (EZH2) transcription and protein expression, resulting in decreased migration, tri-methylation of histone H3 at lysine 27 (H3K27me3) and long non-coding RNA H19 expression (Khan et al., 2021).